Outside of SCLC, ELAVL2 has been shown to be an independent risk factor in esophageal squamous cell carcinoma, and it increases the resistance of these tumor cells to paclitaxel and cisplatin (Zhao et al., 2019). Here, ELAVL2 is linked to small cell lung carcinoma.